Peregrine looks to redefine bavituximab as immunotherapy

23:35 EDT 14 Jul 2013 | SCRIP

Tustin, California-based Peregrine is pressing forward with a Phase III clinical trial that pairs its phosphatidylserine (PS)-targeting monoclonal antibody with the chemotherapeutic agent docetaxel, but the company will continue a review of preclinic...

Original Article: Peregrine looks to redefine bavituximab as immunotherapy

NEXT ARTICLE

More From BioPortfolio on "Peregrine looks to redefine bavituximab as immunotherapy"

Search BioPortfolio:
Loading
Advertisement

Relevant Topic

Prostate Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Advertisement

Searches Linking to this Story